Citation Impact
Citing Papers
ATF6α-Rheb-mTOR signaling promotes survival of dormant tumor cells in vivo
2008
Major Tumor Shrinking and Persistent Molecular Remissions After Consolidation With Bortezomib, Thalidomide, and Dexamethasone in Patients With Autografted Myeloma
2010
In vitro reconstitution of ER-stress induced ATF6 transport in COPII vesicles
2009 StandoutNobel
Ferroptosis regulation by the NGLY1/NFE2L1 pathway
2022 StandoutNobel
The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
2013 StandoutScienceNobel
BCL9 Promotes Tumor Progression by Conferring Enhanced Proliferative, Metastatic, and Angiogenic Properties to Cancer Cells
2009
Hypoxia-Inducible Factor-1-Dependent Repression of E-cadherin in von Hippel-Lindau Tumor Suppressor–Null Renal Cell Carcinoma Mediated by TCF3, ZFHX1A, and ZFHX1B
2006 StandoutNobel
Efficacy of bortezomib in systemic AL amyloidosis with relapsed/refractory clonal disease
2008
The development of proteasome inhibitors as anticancer drugs
2004
The Concept of Synthetic Lethality in the Context of Anticancer Therapy
2005 StandoutNobel
Oncology Meets Immunology: The Cancer-Immunity Cycle
2013 Standout
When hypoxia signalling meets the ubiquitin-proteasomal pathway, new targets for cancer therapy
2004
The Ubiquitin Proteasome System in Neurodegenerative Diseases
2003 StandoutNobel
Rb Regulates Interactions between Hematopoietic Stem Cells and Their Bone Marrow Microenvironment
2007
Promotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene
2003 StandoutNobel
Combining immunotherapy and targeted therapies in cancer treatment
2012
Epithelial-Mesenchymal Transitions in Development and Disease
2009 Standout
Ovarian cancer
2014 Standout
Bcl-2 Antiapoptotic Proteins Inhibit Beclin 1-Dependent Autophagy
2005 Standout
Calcineurin Promotes Hypoxia-inducible Factor 1α Expression by Dephosphorylating RACK1 and Blocking RACK1 Dimerization
2007 StandoutNobel
Treatment of Obesity with Celastrol
2015 Standout
Tumor Metastasis: Molecular Insights and Evolving Paradigms
2011 Standout
Multiple Myeloma
2004
Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways
2005 StandoutNobel
Heat shock protein 90: The cancer chaperone
2007
HSP90 and the chaperoning of cancer
2005 Standout
Osteoporosis: now and the future
2011 Standout
The bone marrow niche for haematopoietic stem cells
2014 StandoutNature
Ubiquitin Ligase Activity of TFIIH and the Transcriptional Response to DNA Damage
2005 StandoutNobel
Fas Ligand-Mediated Apoptosis in Degenerative Disorders of the Brain
2003
Transcription Factor Nrf1 Mediates the Proteasome Recovery Pathway after Proteasome Inhibition in Mammalian Cells
2010
New Approaches and Therapeutics Targeting Apoptosis in Disease
2005
New drugs in multiple myeloma: mechanisms of action and phase I/II clinical findings
2008
Molecular chaperones in protein folding and proteostasis
2011 StandoutNature
IPI-504, a novel and soluble HSP-90 inhibitor, blocks the unfolded protein response in multiple myeloma cells
2007
NF-κB and IKK as therapeutic targets in cancer
2006 Standout
The proteasome: structure, function, and role in the cell
2003
Brown adipose tissue thermogenic adaptation requires Nrf1-mediated proteasomal activity
2018 StandoutNobel
RACK1 Competes with HSP90 for Binding to HIF-1α and Is Required for O2-Independent and HSP90 Inhibitor-Induced Degradation of HIF-1α
2007 StandoutNobel
Systemic amyloidosis
2015 Standout
Clinical update: proteasome inhibitors in hematologic malignancies
2003
Multimodality treatment of cancer with herceptin conjugated, thermomagnetic iron oxides and docetaxel loaded nanoparticles of biodegradable polymers
2012
Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets
2007
Pomalidomide: a novel drug to treat relapsed and refractory multiple myeloma
2013
Argonaute CLIP Defines a Deregulated miR-122-Bound Transcriptome that Correlates with Patient Survival in Human Liver Cancer
2017 StandoutNobel
Tumor-Derived Jagged1 Promotes Osteolytic Bone Metastasis of Breast Cancer by Engaging Notch Signaling in Bone Cells
2011
The blockade of immune checkpoints in cancer immunotherapy
2012 Standout
Transcription factor Ikzf1 associates with Foxp3 to repress gene expression in Treg cells and limit autoimmunity and anti-tumor immunity
2024 StandoutNobel
The proteasome: a suitable antineoplastic target
2004
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
2015 StandoutNature
Repertoires of Autophagy in the Pathogenesis of Ocular Diseases
2015 Standout
XBP1 Links ER Stress to Intestinal Inflammation and Confers Genetic Risk for Human Inflammatory Bowel Disease
2008 Standout
Fas Ligand-Mediated Apoptosis in Degenerative Disorders of the Brain
2003
The molecular characterization and clinical management of multiple myeloma in the post-genome era
2009
Metastatic colonization by circulating tumour cells
2016 StandoutNature
Heat shock protein 90
2003
The role of the ubiquitin/proteasome system in cellular responses to radiation
2003
Microenvironmental regulation of tumor progression and metastasis
2013 Standout
Proteasome Inhibitors: An Expanding Army Attacking a Unique Target
2012
Protein Sequence Editing of SKN-1A/Nrf1 by Peptide:N-Glycanase Controls Proteasome Gene Expression
2019 StandoutNobel
Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics
2009 StandoutNobel
Targeting MET in cancer: rationale and progress
2012
Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction
2009 Standout
Peptidic degron in EID1 is recognized by an SCF E3 ligase complex containing the orphan F-box protein FBXO21
2015 StandoutNobel
Simultaneous inhibition of hsp 90 and the proteasome promotes protein ubiquitination, causes endoplasmic reticulum-derived cytosolic vacuolization, and enhances antitumor activity
2004
Heat-shock protein 90 inhibitors as novel cancer chemotherapeutics – an update
2005
Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma
2009
Molecular and cellular basis for the unique functioning of Nrf1, an indispensable transcription factor for maintaining cell homoeostasis and organ integrity
2016
Novel biologically based therapies for Waldenstrom's macroglobulinemia
2003
Apoptosis: A Review of Programmed Cell Death
2007 Standout
Peptidic degron for IMiD-induced degradation of heterologous proteins
2019 StandoutNobel
Proteasomal Inhibition Attenuates Transcriptional Activity of Hypoxia-Inducible Factor 1 (HIF-1) via Specific Effect on the HIF-1α C-Terminal Activation Domain
2006
Ubiquitination and Proteasomal Degradation of Nucleophosmin-Anaplastic Lymphoma Kinase Induced by 17-Allylamino-Demethoxygeldanamycin
2004
Targeted therapies in control of EMT in carcinoma and fibrosis
2007
Aggregation-Induced Emission: Together We Shine, United We Soar!
2015 Standout
Altered Hsp90 function in cancer: A unique therapeutic opportunity
2004
Adaptive and Maladaptive Cardiorespiratory Responses to Continuous and Intermittent Hypoxia Mediated by Hypoxia-Inducible Factors 1 and 2
2012 StandoutNobel
Nanotechnology for Multimodal Synergistic Cancer Therapy
2017 Standout
Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study
2011
Proteasome Inhibition As a Novel Therapeutic Target in Human Cancer
2005
Adult hematopoietic stem cells lacking Hif-1α self-renew normally
2016 StandoutNobel
Bortezomib: Proteasome Inhibition as an Effective Anticancer Therapy
2006
Precision glycocalyx editing as a strategy for cancer immunotherapy
2016 StandoutNobel
Reactive Oxygen Species (ROS)-Based Nanomedicine
2019 Standout
MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma
2009
Inhibition of Macroautophagy Triggers Apoptosis
2005 Standout
Advances in biology of multiple myeloma: clinical applications
2004
Impact of Natural Products on Developing New Anti-Cancer Agents
2009 Standout
Immune Suppression and Resistance Mediated by Constitutive Activation of Wnt/β-Catenin Signaling in Human Melanoma Cells
2012
Emerging Targets in Photopharmacology
2016 StandoutNobel
Multiple Myeloma
2011 Standout
Reactive oxygen species generating systems meeting challenges of photodynamic cancer therapy
2016 Standout
Insulin-Like Growth Factor I Controls a Mutually Exclusive Association of RACK1 with Protein Phosphatase 2A and β1 Integrin To Promote Cell Migration
2006
Proteasome inhibitors disrupt the unfolded protein response in myeloma cells
2003
Nuclear factor‐erythroid 2‐related factor 1 regulates expression of proteasome genes in hepatocytes and protects against endoplasmic reticulum stress and steatosis in mice
2013
The Antiapoptotic Protein BAG3 Is Expressed in Thyroid Carcinomas and Modulates Apoptosis Mediated by Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand
2006
Randomized Phase III Study of Pegylated Liposomal Doxorubicin Plus Bortezomib Compared With Bortezomib Alone in Relapsed or Refractory Multiple Myeloma: Combination Therapy Improves Time to Progression
2007
The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications
2004
Works of Constantine Mitsiades being referenced
Antitumor activity of lysophosphatidic acid acyltransferase-beta inhibitors, a novel class of agents, in multiple myeloma.
2003
Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers
2011
Regulation of Apo2L/Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Induced Apoptosis in Thyroid Carcinoma Cells
2002
The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: Interplay of growth factors, their receptors and stromal interactions
2006
p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells
2004
Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma
2011
Induction of tumour cell apoptosis by matrix metalloproteinase inhibitors: new tricks from a (not so) old drug
2001
Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model.
2002
Treatment of hematologic malignancies and solid tumors by inhibiting IGF receptor signaling
2005
Tailoring treatment for multiple myeloma patients with relapsed and refractory disease.
2010
Targeting mitochondria to overcome conventional and bortezomib/proteasome inhibitor PS-341 resistance in multiple myeloma (MM) cells
2004
Molecular sequelae of proteasome inhibition in human multiple myeloma cells
2002
Phenotypic and Functional Effects of Heat Shock Protein 90 Inhibition on Dendritic Cell
2007
Targeting the β-catenin/TCF transcriptional complex in the treatment of multiple myeloma
2007
Multicenter, Phase I, Dose-Escalation Trial of Lenalidomide Plus Bortezomib for Relapsed and Relapsed/Refractory Multiple Myeloma
2009